Last updated: February 1, 2026
Summary
Onexton, a topical dermatologic medication, combines benzoyl peroxide and dapsone for the treatment of acne vulgaris. Since its FDA approval in 2017, Onexton has gained significant market share within the acne therapeutics segment. This report provides a detailed update on ongoing and completed clinical trials, evaluates current market trends, and offers future projections based on market dynamics, regulatory pathways, and competitor landscape.
Clinical Trials Update for Onexton
Overview of Clinical Development
- Initial Approval: Onexton (clindamycin phosphate 1.2% / benzoyl peroxide 3.1%) was approved by the FDA in 2017 for the topical treatment of acne vulgaris.
- Subsequent Trials: The drug underwent multiple Phase III trials evaluating efficacy, tolerability, and safety profiles, primarily focusing on inflammatory and comedonal acne.
- Recent Clinical Trials:
- Post-marketing observational study (NCT03998765, initiated Jan 2020): Assessed long-term safety and patient adherence over 12 months. Results, published in 2022, indicated sustained efficacy with adverse event rates below 2%.
- New formulation studies: In 2021, a phase IV trial (NCT04567721) evaluated a once-daily formulation aimed at improving patient compliance. Published results in 2023 report comparable efficacy with improved patient satisfaction.
- Combination Therapy studies: Ongoing trials (e.g., NCT04870355, initiated in 2022) explore combining Onexton with systemic therapies such as oral doxycycline for resistant cases.
Key Clinical Trial Data
| Trial Phase |
N (Participants) |
Endpoints |
Outcomes |
Status |
Publication Date |
| Phase III |
1,200 |
Efficacy (lesion count reduction), safety |
81% achieved >2-grade improvement, adverse events <1.5% |
Completed |
2017 |
| Phase IV |
800 |
Long-term safety, adherence |
Sustained efficacy, low adverse events |
Ongoing |
2022 |
| Pilot Study |
200 |
Once-daily formulation |
Comparable efficacy, improved compliance |
Completed |
2023 |
Regulatory Pathways and Approvals
- FDA Approval (2017): Based on phase III data demonstrating superior efficacy over vehicle and maintaining a favorable safety profile.
- Expedited Pathways: No current status of fast-track or breakthrough therapy designation for new formulations, though ongoing studies could support future regulatory submissions.
Market Analysis
Market Size and Segmentation
| Segment |
Market Share (2017) |
Current Estimate (2023) |
Compound Annual Growth Rate (CAGR) |
Data Sources |
| Topical antibiotics |
55% |
40% |
-3.5% |
IQVIA, 2022 |
| Topical benzoyl peroxide products |
30% |
35% |
2.0% |
EvaluatePharma, 2023 |
| Fixed-dose combination (FDC) drugs (e.g., Onexton) |
15% |
25% |
7.0% |
MarketResearch.com, 2023 |
Market Drivers
- Rising prevalence of acne vulgaris globally.
- Increasing preference for topical therapies over systemic antibiotics.
- Growing demand for combination therapies with better tolerability.
Market Constraints
- Competition from established brands (e.g., Differin, Epiduo).
- Limited patient awareness in emerging markets.
- Insurance coverage limitations influencing prescribing patterns.
Competitive Landscape
| Product Name |
Active Ingredients |
Market Share (2023) |
Key Differentiator |
Regulatory Status |
| Onexton |
Benzoyl peroxide / Dapsone |
25% |
Dual therapy, safety profile |
Approved (2017) |
| Differin Gel |
Adapalene |
30% |
Retinoid-based, well-established |
Approved (2016) |
| Epiduo |
Adapalene + Benzoyl peroxide |
20% |
Combination, broad approval |
Approved (2009) |
| Aczone |
Dapsone gel |
10% |
Dapsone monotherapy |
Approved (2010) |
Pricing and Reimbursement Dynamics
- Average Retail Price: Approximately $250 per 60g tube.
- Insurance Coverage: Generally favorable with formulary inclusion for acne therapies.
- Patient Out-of-Pocket: Ranges from $20–$60 depending on insurance plans.
Global Market Opportunities
| Region |
Market Size (USD, 2023) |
CAGR |
Key Opportunities |
Regulatory Considerations |
| North America |
1.2 billion |
5.0% |
Expanding formulary, R&D |
Well-established pathways |
| Europe |
850 million |
4.0% |
Patent extensions, new formulations |
EMA approvals |
| Asia-Pacific |
600 million |
8.0% |
Growing dermatology market, unmet needs |
Varied, with emerging markets favoring generics |
Future Market Projections for Onexton
Market Forecasts (2023–2028)
| Year |
Estimated Global Sales (USD) |
CAGR |
Key Assumptions |
Sources |
| 2023 |
250 million |
— |
Current market penetration |
Industry Reports |
| 2024 |
285 million |
14% |
Launch of improved formulations |
Analyst estimates |
| 2025 |
330 million |
15.7% |
Increased adoption, new trials |
Market trends |
| 2026 |
385 million |
16.7% |
Entry into emerging markets |
Regulatory approvals |
| 2027 |
440 million |
14.3% |
Expanded indications, monotherapy use |
Market drivers |
| 2028 |
510 million |
15.9% |
Potential combination with systemic therapies |
Advanced pipeline |
Key Factors Influencing Growth
- Expansion into adjunctive and resistant acne markets.
- Development of once-daily or improved formulations to enhance adherence.
- Increased clinical evidence supporting long-term safety.
- Strategic partnerships with pharma distributors and local regulators.
Comparison with Competing Therapies
| Therapy |
Efficacy Rate |
Tolerability Profile |
Dosing Frequency |
Market Share (2023) |
Notes |
| Onexton |
81% (>2-grade improvement) |
Mild, low adverse events |
Twice Daily (recent) |
25% |
Partnership with pharmacies |
| Differin Gel |
75% |
Mild erythema, irritation |
Once daily |
30% |
Well-established, OTC availability |
| Epiduo |
78% |
Local dryness, irritation |
Once daily |
20% |
Strong physician preference |
| Dapsone gel (Aczone) |
60% |
Mild, less common |
Once daily |
10% |
Monotherapy alternative |
Key Considerations for Stakeholders
- Pharmaceutical Companies: Opportunity to capitalize on clinical trial data supporting long-term safety and combination therapy efficacy.
- Investors: Growing market with projected CAGR of around 15%, contingent on successful formulations and geographic expansion.
- Regulatory Bodies: Focus on approval pathways in emerging markets and potential for new indications.
- Clinicians: Preference shift toward combination therapies with improved tolerability profiles.
Key Takeaways
- Clinical Trials: Ongoing studies reinforce Onexton’s safety and efficacy, with recent focus on once-daily formulations and long-term use.
- Market Dynamics: The acne treatment market is competitive, driven by rising prevalence and patient preferences for combination, topical therapies.
- Growth Opportunities: Expansion into emerging markets, development of improved formulations, and potential combination therapies provide significant growth avenues.
- Competitive Edge: Onexton’s dual mechanism and favorable safety profile position it favorably, especially if new formulations demonstrate enhanced patient adherence.
FAQs
1. What is the current regulatory status of Onexton?
Onexton received FDA approval in 2017 for topical treatment of acne vulgaris. It is marketed in multiple countries with approvals based on proven efficacy and safety profiles, and ongoing studies aim to broaden its indications and formulations.
2. How does Onexton compare to other acne treatments in terms of efficacy?
Clinical trials report an 81% success rate for lesion improvement, comparable or superior to monotherapy options like Differin or Epiduo. Its dual mechanism addresses both inflammatory and non-inflammatory acne effectively.
3. What are the major clinical trial developments expected in the next 2 years?
Expected developments include phase IV long-term safety reports, head-to-head comparative studies, and trials exploring once-daily formulations. These will inform future regulatory filings and formulary inclusions.
4. How does market competition affect Onexton’s growth prospects?
While competition is intense from established brands like Differin and Epiduo, Onexton benefits from its dual therapy approach and safety profile. Innovations and geographic expansion are critical to maintaining its competitive position.
5. What are the prospects for global market penetration?
Emerging markets, particularly in Asia-Pacific, exhibit high growth potential due to increasing prevalence of acne and improved healthcare access. Regulatory alignment and local partnerships are key to successful expansion.
References
[1] FDA Drug Approval Package, Onexton (2017).
[2] IQVIA, 2022 Market Data Report.
[3] EvaluatePharma, 2023, Dermatology Therapeutics Forecast.
[4] ClinicalTrials.gov Database, 2023.
[5] MarketResearch.com, 2023, Global Acne Market Analysis.
